Stock listing
Frankfurt:42Z Revolution Medicines, Inc. Aktie
German listing (Frankfurt) of Revolution Medicines, Inc. · home listing NASDAQ:RVMD
Follow Revolution Medicines, Inc. into a list and get an email when it puts out news.
Share price · FWB:42Z
€144.00 EUR -2.45 (-1.7%)
Close on Nov 18, 2026
- Day range
- €144.00 – €149.75 EURNov 18, 2026
- Volume
- 307 sharesNov 18, 2026
- Market cap
- €30.86B EURAt the close on Nov 18, 2026 · price × 214.3M shares outstanding
- 52-week range
- €60.41 – €192.74 EURLowest and highest trades, Nov 19, 2025 – Nov 18, 2026
- Traded on an average day
- €55,830 EURMedian day 81 shares · 8 days with no trades · last 3 months, Aug 18, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RVMD · Home | $159.82 USD | -2.87 (-1.8%) | 2,339,689 | $161.65 | $163.04 | $158.41 | $162.69 | Close on Nov 18, 2026 |
| Frankfurt:42Z | €144.00 EUR | -2.45 (-1.7%) | 307 | €148.15 | €149.75 | €144.00 | €146.45 | Close on Nov 18, 2026 |
Daily closes
Last 3 months, Aug 18, 2026 – Nov 6, 2026 · FWB:42Z · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €164.77 | -1.779 | -1.1% | €160.02 | €166.17 | €159.81 | 292 | |
| €166.55 | -11.85 | -6.6% | €186.71 | €190.20 | €166.23 | 25 | |
| €178.40 | +11.30 | +6.8% | €173.49 | €178.52 | €170.58 | 20 | |
| €167.10 | -3.028 | -1.8% | €168.36 | €168.68 | €166.91 | 5 | |
| €170.13 | +3.835 | +2.3% | €170.13 | €170.13 | €170.13 | 72 | |
| €166.29 | -0.734 | -0.4% | €167.80 | €168.47 | €166.29 | 328 | |
| €167.03 | +0.595 | +0.4% | €167.03 | €167.03 | €167.03 | 49 | |
| €166.43 | +2.936 | +1.8% | €166.43 | €166.43 | €166.43 | 2,170 | |
| €163.50 | -2.03 | -1.2% | €163.50 | €163.50 | €163.50 | 162 | |
| €165.53 | -1.222 | -0.7% | €166.08 | €166.37 | €165.27 | 162 | |
| €166.75 | -3.90 | -2.3% | €167.20 | €167.73 | €165.27 | 257 | |
| €170.65 | -3.535 | -2.0% | €170.65 | €170.65 | €170.65 | 0 | |
| €174.18 | -0.153 | -0.1% | €174.18 | €174.18 | €174.18 | 48 | |
| €174.34 | +13.95 | +8.7% | €162.47 | €175.53 | €162.06 | 70 | |
| €160.39 | -0.501 | -0.3% | €160.39 | €165.23 | €160.09 | 0 | |
| €160.89 | -11.58 | -6.7% | €167.52 | €169.55 | €158.83 | 0 | |
| €172.46 | +3.996 | +2.4% | €172.46 | €172.46 | €172.46 | 0 | |
| €168.47 | -3.18 | -1.9% | €168.47 | €168.47 | €168.47 | 175 | |
| €171.65 | +2.105 | +1.2% | €171.65 | €171.65 | €171.65 | 0 | |
| €169.54 | -0.138 | -0.1% | €169.54 | €169.54 | €169.54 | 496 | |
| €169.68 | +7.002 | +4.3% | €169.68 | €169.68 | €169.68 | 101 | |
| €162.68 | -14.81 | -8.3% | €177.56 | €177.72 | €162.42 | 1,242 | |
| €177.49 | -7.00 | -3.8% | €178.07 | €181.12 | €176.89 | 16 | |
| €184.49 | +1.912 | +1.0% | €184.49 | €184.49 | €184.49 | 41 | |
| €182.58 | +0.046 | 0.0% | €182.58 | €182.58 | €182.58 | 0 | |
| €182.53 | -2.003 | -1.1% | €182.53 | €182.53 | €182.53 | 66 | |
| €184.53 | +5.212 | +2.9% | €182.12 | €184.92 | €181.07 | 49 | |
| €179.32 | +1.816 | +1.0% | €179.32 | €179.32 | €179.32 | 0 | |
| €177.51 | -2.336 | -1.3% | €176.21 | €177.96 | €175.93 | 179 | |
| €179.84 | +4.901 | +2.8% | €179.56 | €181.96 | €178.92 | 11 | |
| €174.94 | +7.388 | +4.4% | €174.94 | €174.94 | €174.94 | 143 | |
| €167.55 | +0.745 | +0.4% | €168.31 | €168.85 | €167.55 | 82 | |
| €166.81 | -1.365 | -0.8% | €167.06 | €167.46 | €166.74 | 173 | |
| €168.17 | -1.105 | -0.7% | €168.27 | €168.56 | €165.75 | 13 | |
| €169.28 | -0.343 | -0.2% | €167.99 | €170.58 | €167.93 | 352 | |
| €169.62 | -2.392 | -1.4% | €169.62 | €169.62 | €169.62 | 3,444 | |
| €172.01 | -1.131 | -0.7% | €172.47 | €173.05 | €172.01 | 2 | |
| €173.14 | -3.787 | -2.1% | €176.69 | €176.98 | €171.17 | 690 | |
| €176.93 | +2.739 | +1.6% | €176.93 | €176.93 | €176.93 | 100 | |
| €174.19 | -1.092 | -0.6% | €174.19 | €174.19 | €174.19 | 32 | |
| €175.28 | +0.575 | +0.3% | €175.34 | €175.34 | €175.11 | 270 | |
| €174.71 | -5.717 | -3.2% | €177.43 | €181.78 | €174.43 | 20 | |
| €180.43 | -0.125 | -0.1% | €177.77 | €180.61 | €176.85 | 55 | |
| €180.55 | -2.436 | -1.3% | €180.77 | €181.44 | €180.55 | 185 | |
| €182.99 | -0.047 | 0.0% | €181.51 | €184.34 | €180.85 | 57 | |
| €183.03 | +1.091 | +0.6% | €182.53 | €183.24 | €181.64 | 258 | |
| €181.94 | +2.365 | +1.3% | €180.75 | €183.60 | €179.95 | 306 | |
| €179.58 | +1.855 | +1.0% | €181.08 | €182.72 | €179.58 | 110 | |
| €177.72 | +1.898 | +1.1% | €177.70 | €178.09 | €177.51 | 103 | |
| €175.82 | -5.365 | -3.0% | €179.38 | €180.72 | €175.40 | 406 | |
| €181.19 | -9.215 | -4.8% | €190.22 | €191.98 | €179.44 | 4,732 | |
| €190.40 | +10.32 | +5.7% | €191.25 | €192.74 | €188.93 | 761 | |
| €180.08 | -0.443 | -0.2% | €180.08 | €180.08 | €180.08 | 164 | |
| €180.52 | +2.604 | +1.5% | €180.52 | €180.52 | €180.52 | 0 | |
| €177.92 | -2.521 | -1.4% | €178.89 | €181.70 | €175.53 | 16 | |
| €180.44 | -0.791 | -0.4% | €180.37 | €180.57 | €180.09 | 45 | |
| €181.23 | -6.685 | -3.6% | €185.11 | €185.53 | €180.08 | 81 | |
| €187.92 | +5.315 | +2.9% | €186.84 | €189.36 | €183.35 | 256 | |
| €182.60 | +0.281 | +0.2% | €182.88 | €183.09 | €182.60 | 40 |
- Ticker
- Frankfurt:42Z
- Asset type
- Stock
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Latest earnings call · Nov 4, 2026
Revolution Medicines (NASDAQ:RVMD) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 26, 2026
Investor Presentation (August 2026)
Investor deck · 33 slides
Calls
Replays
Revolution Medicines (NASDAQ:RVMD) Q3 2026 Earnings Call
Wed, Nov 04, 2026 · 4:30 PM ET
Watch TranscriptRevolution Medicines (NASDAQ:RVMD) Q2 2026 Earnings Call
Wed, Aug 05, 2026 · 4:30 PM ET
Watch TranscriptRevolution Medicines (NASDAQ:RVMD) Q1 2026 Earnings Call
Wed, May 06, 2026 · 4:30 PM ET
Watch Transcript
Latest news
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Nov 4, 2026
Closed €166.55 (-6.6%) on Nov 5, 2026
Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
Oct 30, 2026
Closed €170.13 (+2.3%) on Nov 2, 2026
Revolution Medicines to Participate in November 2026 Investor Conferences
Oct 27, 2026
Closed €166.43 (+1.8%) on Oct 28, 2026
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
Oct 23, 2026
Closed €166.75 (-2.3%) on Oct 23, 2026
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
Oct 21, 2026
Closed €170.65 (-2.0%) on Oct 22, 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
Oct 20, 2026
Closed €174.34 (+8.7%) on Oct 20, 2026
Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Oct 15, 2026
Closed €172.46 (+2.4%) on Oct 15, 2026
Financings
Public offering of common stock
Apr 17, 2026
Closed: US$1.5B raised · US$142 a share · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), LifeSci Capital
Use of proceeds: General corporate purposes, including R&D, potential commercialization of product candidates, G&A expenses and capital expenditures
Announced Apr 13, 2026 · Made bigger Apr 15, 2026 · Closed Apr 17, 2026
0.50% convertible senior notes due 2033
Apr 17, 2026
Closed: US$500M raised · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), LifeSci Capital
Use of proceeds: General corporate purposes, including R&D, potential commercialization of product candidates, G&A expenses and capital expenditures
Announced Apr 13, 2026 · Made bigger Apr 15, 2026 · Closed Apr 17, 2026
Synthetic royalty on daraxonrasib sales
Jun 24, 2025
Tranche closed: US$250M raised · TD Securities
Dealers: TD Securities
Buyers: Royalty Pharma (up to $1.25 billion in exchange for tiered royalties on daraxonrasib net sales)
Use of proceeds: Support independent global development and commercialization of its RAS(ON) inhibitor portfolio
Public offering of common stock and pre-funded warrants
Dec 5, 2024
Closed: US$862.5M raised · US$46 a share · J.P. Morgan +4
Dealers: J.P. Morgan (co-lead), TD Cowen (co-lead), Goldman Sachs & Co. LLC (co-lead), Guggenheim Securities (co-lead), UBS Investment Bank
Announced Dec 2, 2024 · Made bigger Dec 3, 2024 · Closed Dec 5, 2024
Decks
Investor Presentation (August 2026)
Investor deck · 33 slides · Aug 26, 2026
Investor Presentation (August 2026)
Investor deck · 99 slides · August 2026
Technical Presentation (July 2026)
Technical · 15 slides · July 2026
AACR 2026
Conference · 15 slides · April 2026
Revolution Medicines, Inc. on 6ix
- News releases
- 46 in the last 12 months · 173 in all · newest Nov 16, 2026 · oldest 2020
- Calls
- 22 calls with a replay · 22 with a transcript · latest Nov 4, 2026
- Decks
- 16 decks · latest Aug 26, 2026
Where Revolution Medicines, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RVMD · Home listing | NASDAQ | United States | USD |
| gettex:42Z | gettex | Germany | EUR |
| LS Exchange:A2PYWG | LS Exchange | Germany | EUR |
| Milan:1RVMD | Milan | Italy | EUR |
| Tradegate:42Z | Tradegate | Germany | EUR |
| BX Swiss:RVMD | BX Swiss | Switzerland | CHF |
| BOATS:RVMD | BOATS | United States | USD |
| Lang & Schwarz:A2PYWG | Lang & Schwarz | Germany | EUR |
| BMV:RVMD | BMV | Mexico | MXN |
| Dusseldorf:42Z | Dusseldorf | Germany | EUR |
| Frankfurt:42Z · This page | Frankfurt | Germany | EUR |
| Hamburg:42Z | Hamburg | Germany | EUR |
| Munich:42Z | Munich | Germany | EUR |
| Stuttgart:42Z | Stuttgart | Germany | EUR |
| BIVA:RVMD | BIVA | Mexico | MXN |
| Hanover:42Z | Hanover | Germany | EUR |
| Xetra:42Z | Xetra | Germany | EUR |
Log in to ask 6ix AI your own questions about Revolution Medicines, Inc.